{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:39:53Z","timestamp":1790811593725,"version":"4.1.0"},"reference-count":169,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Trade, Industry &amp; Resources","award":["RS-2025-13642970"],"award-info":[{"award-number":["RS-2025-13642970"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) are a potent class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. By targeting tumor cells with minimal impact on healthy tissues, ADCs achieve a favorable balance between efficacy and systemic toxicity. This therapeutic modality has demonstrated significant clinical success, as evidenced by the FDA approval of 15 ADCs by 2025, with one later withdrawn due to safety concerns, and indications continuing to expand across various cancer types. Beyond monotherapy, there is growing interest in ADC-based combination strategies aimed at enhancing therapeutic outcomes and managing resistance. Several combinations, especially with chemotherapy, immune checkpoint inhibitors, or molecularly targeted agents, have gained regulatory approval or advanced to late-stage clinical trials. While dual-agent regimens have historically dominated the research landscape, multiplet combinations are also gaining traction and represent a promising frontier in oncology. This evolving paradigm highlights the need for a comprehensive understanding of current ADC combination approaches. In this review, we examine recent clinical advances in ADC-based combinations, with a particular focus on regimens that incorporate FDA-approved ADCs. We also discuss the progression from dual-agent approaches to more complex multiplet strategies across a range of tumor types.<\/jats:p>","DOI":"10.3390\/pharmaceutics17121581","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:52:24Z","timestamp":1765205544000},"page":"1581","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Strategic Combinations of Antibody\u2013Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens"],"prefix":"10.3390","volume":"17","author":[{"given":"Heewon","family":"Jang","sequence":"first","affiliation":[{"name":"College of Pharmacy, Dongduk Women\u2019s University, Seoul 02748, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0037-1560","authenticated-orcid":false,"given":"Ji-Eun","family":"Chang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dongduk Women\u2019s University, Seoul 02748, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): Current and Future Biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody\u2013Drug Conjugates: In Search of Partners of Choice","volume":"9","author":"Genta","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pysz, I., Jackson, P.J.M., and Thurston, D.E. (2019). Introduction to Antibody\u2013Drug Conjugates (ADCs). Cytotoxic Payloads for Antibody\u2014Drug Conjugates, The Royal Society of Chemistry.","DOI":"10.1039\/9781788012898-00001"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pettinato, M.C. (2021). Introduction to Antibody-Drug Conjugates. Antibodies, 10.","DOI":"10.3390\/antib10040042"},{"key":"ref_5","unstructured":"(2025, September 01). Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast."},{"key":"ref_6","unstructured":"(2025, September 01). Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer."},{"key":"ref_7","unstructured":"(2025, September 01). Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of Gemtuzumab Ozogamicin on Survival of Adult Patients with De-Novo Acute Myeloid Leukaemia (ALFA-0701): A Randomised, Open-Label, Phase 3 Study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results from the Randomized Phase III Children\u2019s Oncology Group Trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized Phase 3 ALCANZA Study of Brentuximab Vedotin vs Physician\u2019s Choice in Cutaneous T-Cell Lymphoma: Final Data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab Emtansine versus Capecitabine plus Lapatinib in Patients with Previously Treated HER2-Positive Advanced Breast Cancer (EMILIA): A Descriptive Analysis of Final Overall Survival Results from a Randomised, Open-Label, Phase 3 Trial","volume":"18","author":"Miles","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab Ozogamicin versus Standard of Care in Relapsed or Refractory Acute Lymphoblastic Leukemia: Final Report and Long-term Survival Follow-up from the Randomized, Phase 3 INO-VATE Study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","article-title":"Inotuzumab Ozogamicin Combined with Chemotherapy in Pediatric B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia: Results of the Phase IB ITCC-059 Trial","volume":"109","author":"Pennesi","year":"2024","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab Pasudotox in Relapsed\/Refractory Hairy Cell Leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab Vedotin after PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma (EV-201): A Multicentre, Single-Arm, Phase 2 Trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab Deruxtecan: First Approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105082","DOI":"10.1016\/j.esmoop.2025.105082","article-title":"Patient-Reported Outcomes with Trastuzumab Deruxtecan in Hormone Receptor-Positive, HER2-Low or HER2-Ultralow Metastatic Breast Cancer: Results from the Randomized DESTINY-Breast06 Trial","volume":"10","author":"Hu","year":"2025","journal-title":"ESMO Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab Deruxtecan in HER2-Positive Advanced Gastric Cancer: Exploratory Biomarker Analysis of the Randomized, Phase 2 DESTINY-Gastric01 Trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results from the Randomized, Phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non\u2013Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab Deruxtecan in Patients with HER2-Positive Advanced Colorectal Cancer (DESTINY-CRC02): Primary Results from a Multicentre, Randomised, Phase 2 Trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase I\/II IMMU-132-01 Basket Trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall Survival with Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing after Platinum-Based Chemotherapy and Checkpoint Inhibitors: Updated Safety and Efficacy Outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and Safety of Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer (InnovaTV 204\/GOG-3023\/ENGOT-Cx6): A Multicentre, Open-Label, Single-Arm, Phase 2 Study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1158\/2767-9764.CRC-25-0057","article-title":"Preclinical Activity of Datopotamab Deruxtecan, an Antibody\u2013Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma","volume":"5","author":"Greenman","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","article-title":"FDA Approval Summary: Datopotamab Deruxtecan-Dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer","volume":"31","author":"Royce","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic Non\u2013Small Cell Lung Cancer with Actionable Genomic Alterations: Results from the Phase II TROPION-Lung05 Study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients with Previously Treated C-Met Protein\u2013Overexpressing Advanced Nonsquamous EGFR -Wildtype Non\u2013Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjh.70028","article-title":"A Phase Ib\/II Trial Combining Brentuximab Vedotin with Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients with Untreated Classical Hodgkin Lymphoma: A Multicentre GELTAMO Trial","volume":"207","author":"Carpio","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab Vedotin plus Doxorubicin and Dacarbazine in Nonbulky Limited-Stage Classical Hodgkin Lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results from the InnovaTV 205\/GOG-3024\/ENGOT-Cx8 Study","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive Chemotherapy with or without Gemtuzumab Ozogamicin in Patients with NPM1-Mutated Acute Myeloid Leukaemia (AMLSG 09\u201309): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"10","author":"Weber","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab Vedotin with Dacarbazine or Nivolumab as Frontline CHL Therapy for Older Patients Ineligible for Chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22 + Philadelphia Chromosome\u2013Negative B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2024-206161","article-title":"Phase 1\/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia","volume":"144","author":"Chan","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.23.00943","article-title":"Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients with Newly Diagnosed AML and Overall Survival in Patients with NPM1 and FLT3 Mutations","volume":"42","author":"Russell","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab Vedotin plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone Followed by Brentuximab Vedotin Consolidation in CD30-Positive Peripheral T-Cell Lymphomas: A Multicentre, Single-Arm, Phase 2 Study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2023-181397","article-title":"Brentuximab Vedotin in Combination with Methotrexate, L-Asparaginase, and Dexamethasone (B-MAD) As Frontline Treatment for Patients with Extranodal NK\/T-Cell Lymphoma","volume":"142","author":"Bunworasate","year":"2023","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2024.0967","article-title":"Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults with Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial","volume":"10","author":"Kopmar","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years with Philadelphia Chromosome\u2013Negative B-Precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2023.12.017","article-title":"A Phase I Study of Mirvetuximab Soravtansine and Gemcitabine in Patients with FR\u03b1-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer, or Triple Negative Breast Cancer","volume":"182","author":"Cristea","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","article-title":"Mechanism of Action and Future Perspectives of ADCs in Combination with Immune Checkpoint Inhibitors for Solid Tumors","volume":"25","author":"Lv","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2217\/fon-2023-0230","article-title":"TROPION-Lung08: Phase III Study of Datopotamab Deruxtecan plus Pembrolizumab as First-Line Therapy for Advanced NSCLC","volume":"19","author":"Levy","year":"2023","journal-title":"Future Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, Nivolumab, and Brentuximab Vedotin Combination Therapies in Patients with Relapsed or Refractory Hodgkin Lymphoma: Phase 1 Results of an Open-Label, Multicentre, Phase 1\/2 Trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1158\/1078-0432.CCR-24-1478","article-title":"Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1\u2013Pretreated Metastatic Non\u2013Small Cell Lung Cancer and Metastatic Cutaneous Melanoma","volume":"31","author":"Lee","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/bloodadvances.2025016470","article-title":"Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-Term Results","volume":"9","author":"Cheson","year":"2025","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab Vedotin plus Nivolumab after Autologous Haematopoietic Stem-Cell Transplantation for Adult Patients with High-Risk Classic Hodgkin Lymphoma: A Multicentre, Phase 2 Trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1182\/bloodadvances.2023010254","article-title":"Nivolumab Combined with Brentuximab Vedotin for R\/R Primary Mediastinal Large B-Cell Lymphoma: A 3-Year Follow-Up","volume":"7","author":"Zinzani","year":"2023","journal-title":"Blood Adv."},{"key":"ref_60","first-page":"2075","article-title":"Nivolumab and Brentuximab Vedotin with or without Bendamustine for R\/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults","volume":"141","author":"Leblanc","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2023-184531","article-title":"Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed\/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)","volume":"142","author":"Diefenbach","year":"2023","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"PO3-20-01","DOI":"10.1158\/1538-7445.SABCS23-PO3-20-01","article-title":"Abstract PO3-20-01: ASTEFANIA: A Phase III Study of Ado-Trastuzumab Emtansine plus Atezolizumab or Placebo as Adjuvant Therapy in Patients with Residual Invasive Breast Cancer after Neoadjuvant HER2-Targeted Therapy and Chemotherapy","volume":"84","author":"Schmid","year":"2024","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2024.42.16_suppl.3100","article-title":"MyTACTIC: Activity of Targeted Therapy in Patients (Pts) with Advanced Solid Tumors Harboring Specific Biomarkers","volume":"42","author":"Schwartzberg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab Govitecan in Combination with Pembrolizumab for Patients with Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1200\/JCO.2024.42.16_suppl.8592","article-title":"Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) in First-Line (1L) Metastatic Non-Small Cell Lung Cancer (MNSCLC) with PD-L1 \u2265 50%: Cohort A of EVOKE-02","volume":"42","author":"Patel","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","article-title":"OptimICE-RD: Sacituzumab Govitecan + Pembrolizumab vs Pembrolizumab (\u00b1 Capecitabine) for Residual Triple-Negative Breast Cancer","volume":"20","author":"Tolaney","year":"2024","journal-title":"Future Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"LBA109","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1\u2013Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results from the Randomized Phase 3 ASCENT-04\/KEYNOTE-D19 Study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.annonc.2025.05.010","article-title":"Avelumab plus Sacituzumab Govitecan versus Avelumab Monotherapy as First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma: JAVELIN Bladder Medley Interim Analysis","volume":"36","author":"Tsiatas","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"TPS4622","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4622","article-title":"Adjuvant Sacituzumab Govitecan (SG) plus Nivolumab (N) in Patients (Pts) with Muscle-Invasive Urothelial Carcinoma (UC) at High-Risk for Recurrence","volume":"43","author":"Mar","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S1141","DOI":"10.1016\/j.annonc.2024.08.2054","article-title":"1969P Phase I\/II Study of Ipilimumab plus Nivolumab Combined with Sacituzumab Govitecan in Patients with Metastatic Cisplatin-Ineligible Urothelial Carcinoma","volume":"35","author":"Jain","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"103203","DOI":"10.1016\/j.esmoop.2024.103203","article-title":"181O Interim Analysis (IA) of the Atezolizumab (Atezo) + Sacituzumab Govitecan (SG) Arm in Patients (Pts) with Triple-Negative Breast Cancer (TNBC) in MORPHEUS-Pan BC: A Phase Ib\/II Study of Multiple Treatment (Tx) Combinations in Pts with Locally Advance","volume":"9","author":"Schmid","year":"2024","journal-title":"ESMO Open"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"TPS4627","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4627","article-title":"SMART: A Phase II Study of Sacituzumab Govitecan (SG) with or without Atezolizumab Immunotherapy in Rare Genitourinary (GU) Tumors Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder\/Urinary Tract Cancer, Renal Medullary Carcinoma (RMC) and Peni","volume":"42","author":"Kydd","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2023.41.6_suppl.439","article-title":"Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","volume":"41","author":"Milowsky","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"TPS4628","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4628","article-title":"A Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","volume":"42","author":"Chandran","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14796694.2025.2497719","article-title":"E-VIRTUE: A Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors\u2014Design and Rationale","volume":"21","author":"Chandran","year":"2025","journal-title":"Future Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"PD11-08","DOI":"10.1158\/1538-7445.SABCS22-PD11-08","article-title":"Abstract PD11-08: PD11-08 Trastuzumab Deruxtecan (T-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced\/Metastatic Hormone Receptor-Negative (HR\u2212), HER2-Low Breast Cancer: Updated Results from BEGONIA, a Phase 1b\/2 Study","volume":"83","author":"Schmid","year":"2023","journal-title":"Cancer Res."},{"key":"ref_78","first-page":"A787","article-title":"695 Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) with Durvalumab in Patients with Non-Small Cell Lung Cancer (HER2 Altered NSCLC) Who Progressed on Anti-PD1\/PD-L1 Therapy (HUDSON)","volume":"11","author":"Cheema","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"PO3-20-06","DOI":"10.1158\/1538-7445.SABCS23-PO3-20-06","article-title":"Abstract PO3-20-06: TRUDI: A Phase II Study of Neoadjuvant TRastuzumab DerUxtecan and Durvalumab for Stage III HER2-Expressing Inflammatory Breast Cancer","volume":"84","author":"Tarantino","year":"2024","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.iotech.2024.100747","article-title":"118MO Trastuzumab Deruxtecan (T-DXd) and Pembrolizumab in Immuno-Oncology (IO)-Naive HER2-Expressing or HER2-Mutant Non-Small Cell Lung Cancer (NSCLC): Interim Analysis of a Phase Ib Study","volume":"24","author":"Italiano","year":"2024","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"P5-07-29","DOI":"10.1158\/1557-3265.SABCS24-P5-07-29","article-title":"Abstract P5-07-29: Trastuzumab Deruxtecan With Pembrolizumab in Previously Treated HER2-Expressing Advanced or Metastatic Breast Cancer: Interim Analyses of the Breast Cohorts from the Open-Label, Multicenter, Phase 1b Study DS8201-A-U106","volume":"31","author":"Rugo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","article-title":"Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FR\u03b1)\u2013Targeting Antibody-Drug Conjugate (ADC), in Combination with Pembrolizumab in Patients with Platinum-Resistant Ovarian Cancer","volume":"200","author":"Matulonis","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"CT008","DOI":"10.1158\/1538-7445.AM2024-CT008","article-title":"Abstract CT008: A Phase 2, Two-Stage Study of Mirvetuximab Soravtansine (IMGN853) in Combination with Pembrolizumab in Patients with Microsatellite Stable (MSS) Recurrent or Persistent Endometrial Cancer","volume":"84","author":"Porter","year":"2024","journal-title":"Cancer Res."},{"key":"ref_85","unstructured":"(2025, September 01). AstraZeneca Datopotamab Deruxtecan plus IMFINZI\u00ae (Durvalumab) Demonstrated Robust and Durable Tumor Responses in 1st-Line Treatment of Patients with Metastatic Triple-Negative Breast Cancer in BEGONIA Phase Ib\/II Trial. Available online: https:\/\/www.astrazeneca-us.com\/media\/press-releases\/2023\/datopotamab-deruxtecan-plus-imfinzi-durvalumab-demonstrated-robust-and-durable-tumor-responses-in-1st-line-treatment-of-patients-with-metastatic-triple-negative-breast-cancer-in-begonia-phase-ib-ii-trial-10222023.html."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab\u2013Deruxtecan plus Durvalumab in Early-Stage Breast Cancer: The Sequential Multiple Assignment Randomized I-SPY2.2 Phase 2 Trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"17588359241248336","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: A Randomized Phase III Global Trial of Datopotamab Deruxtecan \u00b1 Durvalumab in Patients with Triple-Negative Breast Cancer and Residual Invasive Disease at Surgical Resection after Neoadjuvant Therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"17588359251316176","DOI":"10.1177\/17588359251316176","article-title":"TROPION-Breast04: A Randomized Phase III Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab Followed by Adjuvant Durvalumab versus Standard of Care in Patients with Treatment-Na\u00efve Early-Stage Triple Negative or HR-Low\/HER2\u2212 Breast Can","volume":"17","author":"McArthur","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"17588359251327992","DOI":"10.1177\/17588359251327992","article-title":"TROPION-Breast05: A Randomized Phase III Study of Dato-DXd with or without Durvalumab versus Chemotherapy plus Pembrolizumab in Patients with PD-L1-High Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer","volume":"17","author":"Schmid","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2025.43.16_suppl.8521","article-title":"First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) + Rilvegostomig in Advanced or Metastatic Non-Small Cell Lung Cancer (a\/MNSCLC): Results from TROPION-Lung04 (Cohort 5)","volume":"43","author":"Waqar","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1556-0864(25)00317-X","article-title":"122TiP: TROPION-Lung10: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Rilvegostomig in Non-Squamous (NSQ) Advanced\/Metastatic (a\/m) Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression and without Actionable Genomic Alterations (AGAs)","volume":"20","author":"Solomon","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"LBA1004","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1004","article-title":"SACI-IO HR+: A Randomized Phase II Trial of Sacituzumab Govitecan with or without Pembrolizumab in Patients with Metastatic Hormone Receptor-Positive\/HER2-Negative Breast Cancer","volume":"42","author":"Kim","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a Phase Ib Study of Telisotuzumab Vedotin in Combination with Osimertinib in Patients with C-Met Protein-Overexpressing, EGFR-Mutated Locally Advanced\/Metastatic Non-Small-Cell Lung Cancer (NSCLC) after Progression on Prior Osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","article-title":"Maintenance with Mirvetuximab Soravtansine plus Bevacizumab vs Bevacizumab in FR\u03b1-High Platinum-Sensitive Ovarian Cancer","volume":"20","author":"Myers","year":"2024","journal-title":"Future Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2024-198727","article-title":"A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"144","author":"Kambhampati","year":"2024","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1016\/S2152-2650(24)01519-2","article-title":"ABCL-353 Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7)","volume":"24","author":"Ayers","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.clml.2024.03.013","article-title":"Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma","volume":"24","author":"Mei","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_99","first-page":"100481","article-title":"Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC","volume":"4","author":"Jebbink","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"GS01-10","DOI":"10.1158\/1538-7445.SABCS23-GS01-10","article-title":"Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer","volume":"84","author":"Hurvitz","year":"2024","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"CT289","DOI":"10.1158\/1538-7445.AM2024-CT289","article-title":"Abstract CT289: A Phase II Study of Tucatinib and Ado-Trastuzumab Emtansine (T-DM1) in Patients with HER2-Positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)","volume":"84","author":"Dumbrava","year":"2024","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","article-title":"Neratinib and Ado-Trastuzumab Emtansine for Pretreated and Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022","volume":"35","author":"Freedman","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13058-024-01823-8","article-title":"NSABP FB-10: A Phase Ib\/II Trial Evaluating Ado-Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer","volume":"26","author":"Jacobs","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2023-174216","article-title":"A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults","volume":"142","author":"Luskin","year":"2023","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-Free Treatment with Inotuzumab Ozogamicin and Blinatumomab for Older Adults with Newly Diagnosed, Ph-Negative, CD22-Positive, B-Cell Acute Lymphoblastic Leukemia: Alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2024-194581","article-title":"A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL)","volume":"144","author":"Chavez","year":"2024","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2023-177588","article-title":"Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit\/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2352-3026(25)00207-8","article-title":"18th International Conference on Malignant Lymphoma","volume":"12","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b\/2 Trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ajh.27341","article-title":"Polatuzumab Vedotin, Venetoclax, and an anti-CD20 Monoclonal Antibody in Relapsed\/Refractory B-cell non-Hodgkin Lymphoma","volume":"99","author":"Yuen","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s00277-025-06412-z","article-title":"Polatuzumab Vedotin, Zanubrutinib and Rituximab (Pola-ZR) Achieved Rapid and Deep Response in Untreated Frail and Elderly DLBCL","volume":"104","author":"Ren","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2352-3026(23)00345-9","article-title":"Polatuzumab Vedotin plus Rituximab and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Cohort of a Multicentre, Single-Arm, Phase 1b\/2 Study","volume":"11","author":"Abrisqueta","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1182\/blood-2024-198294","article-title":"Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R2) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2024-194328","article-title":"Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extend Follow-Up of a Phase Ib\/II Study","volume":"144","author":"Hutchings","year":"2024","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2025.43.5_suppl.808","article-title":"ETCTN 10483: Phase Ib Trial of Erdafitinib (E) Combined with Enfortumab Vedotin (EV) Following Platinum and PD-1\/L1 Inhibitors for Metastatic Urothelial Carcinoma (MUC) with FGFR3\/2 Genetic Alterations (GAs)","volume":"43","author":"Jain","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1200\/JCO.2024.42.16_suppl.4586","article-title":"Updated Interim Analysis of a Phase I\/Ib Study of Enfortumab Vedotin plus Cabozantinib in Patients with Metastatic Urothelial Carcinoma","volume":"42","author":"Brown","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2024.42.16_suppl.1009","article-title":"DESTINY-Breast07: Dose-Expansion Interim Analysis of T-DXd Monotherapy and T-DXd + Pertuzumab in Patients with Previously Untreated HER2+ MBC","volume":"42","author":"Andre","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_118","first-page":"1","article-title":"7O Trastuzumab Deruxtecan (T-DXd) \u00b1 Pertuzumab (P) in Previously Untreated HER2+ Metastatic Breast Cancer (MBC): Clinical Efficacy and Exploratory Subgroup Analyses in DESTINY-Breast07","volume":"10","author":"Fabbri","year":"2025","journal-title":"ESMO Open"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.annonc.2024.05.413","article-title":"501TiP Valemetostat and Trastuzumab Deruxtecan (T-DXd) in Previously Treated Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma","volume":"35","author":"Shitara","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_120","unstructured":"Naito, Y., Sands, J., Tolaney, S.M., Ueno, N.T., Spira, A., Yamamoto, N., Janjigian, Y., Damodaran, S., Meric-Bernstam, F., and Modi, S. (2025, January 6\u20138). Valemetostat Plus Trastuzumab Deruxtecan (T-DXd) or Datopotamab Deruxtecan (Dato-DXd) in Patients with Solid Tumors. Proceedings of the Annual Meeting of the Japanese Society of Medical Oncology (JSMO), Kobe, Japan."},{"key":"ref_121","first-page":"TPS509","article-title":"Beamion BCGC-1: A Phase Ib\/II Trial of the HER2-Selective Tyrosine Kinase Inhibitor (TKI) Zongertinib (BI 1810631) + Trastuzumab Deruxtecan (T-DXd) or Trastuzumab Emtansine (T-DM1) for Patients with Metastatic Breast Cancer (MBC) and Metastatic Gastric, G.J","volume":"43","author":"Nakayama","year":"2025","journal-title":"Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","article-title":"Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial","volume":"29","author":"Abel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab Tesirine with Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Centre, Single-Arm, Phase 2 Trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1016\/S2152-2650(23)01332-0","article-title":"ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R\/R DLBCL","volume":"23","author":"Kwiatek","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"CT052","DOI":"10.1158\/1538-7445.AM2023-CT052","article-title":"Abstract CT052: A Phase 1\/2 Randomized Study of Imvotamab Monotherapy and in Combination with Loncastuximab Tesirine in Relapsed\/Refractory Non-Hodgkin Lymphomas","volume":"83","author":"Diefenbach","year":"2023","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FR\u03b1)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","article-title":"1O: Osimertinib (Osi) + Datopotamab Deruxtecan (Dato-DXd) in Patients (Pts) with EGFR-Mutated (EGFRm) Advanced NSCLC (ANSCLC) Whose Disease Progressed on First-Line (1L) Osi: ORCHARD","volume":"20","author":"Le","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1556-0864(25)00318-1","article-title":"123TiP: TROPION-Lung14: A Phase III Study of Osimertinib \u00b1 Datopotamab Deruxtecan (Dato-DXd) as First-Line (1L) Treatment for Patients with EGFR-Mutated Locally Advanced or Metastatic (LA\/M) Non-Small Cell Lung Cancer (NSCLC)","volume":"20","author":"Goldberg","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_130","unstructured":"Daiichi Sankyo Company, L.A.P (2025, September 01). Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. Available online: https:\/\/daiichisankyo.us\/press-releases\/-\/article\/three-phase-3-trials-of-datopotamab-deruxtecan-based-combinations-initiated-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.annonc.2025.01.008","article-title":"Telisotuzumab Vedotin and Osimertinib: The METamorphosis of Epidermal Growth Factor Receptor-Mutant Lung Cancer?","volume":"36","author":"Remon","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"TPS4180","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4180","article-title":"A Phase 1b, Multicenter, Open-Label Study of Valemetostat in Combination with DXd Antibody Drug Conjugates (ADCs), Trastuzumab Deruxtecan (T-DXd) or Datopotamab Deruxtecan (Dato-DXd), in Patients with Solid Tumors","volume":"42","author":"Sands","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"TPS424","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS424","article-title":"(Nanu) Phase 1b\/2, Open-Label Dose-Escalation and -Expansion Study Evaluating Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Patients (Pts) with HER2+ and HER2-Low Gastric Cancer (GC): DESTINY-Gastric03 (DG-03)","volume":"42","author":"Janjigian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"S1502","DOI":"10.1016\/j.annonc.2024.10.282","article-title":"264TiP A Phase Ib\/II Open-Label Study Evaluating Trastuzumab Deruxtecan (T-DXd) in Combination with Rilvegostomig and Chemotherapy in Patients with HER2-Positive (HER2+) and HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma (GEJA): DESTINY-Gast","volume":"35","author":"Janjigian","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2025.43.4_suppl.448","article-title":"Updated Results from the Trastuzumab Deruxtecan (T-DXd) 5.4 Mg\/Kg Triplet Combination of DESTINY-Gastric03 (DG-03): First-Line (1L) T-DXd with Fluoropyrimidine (FP) and Pembrolizumab in Advanced\/Metastatic HER2-Positive (HER2+) Esophageal Adenocarcinoma","volume":"43","author":"Janjigian","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_137","unstructured":"(2025, September 01). Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"TPS4207","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4207","article-title":"An Open-Label, Randomized, Multicenter, Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) + Chemotherapy (Chemo) \u00b1 Pembrolizumab (Pembro) versus Chemo + Trastuzumab \u00b1 Pembro in First-Line Metastatic HER2+ Gastric or Gastroesophageal Junction (GEJ) Cancer: DESTINY-Gastric05","volume":"43","author":"Shitara","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S848","DOI":"10.1016\/j.annonc.2023.09.2538","article-title":"1507TiP Phase Ib Multicenter Study of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy with or without Chemotherapy in First-Line Treatment of Patients (Pts) with Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and HER2 Overexpression (OE): DESTINY-Lung03","volume":"34","author":"Planchard","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jtho.2024.09.082","article-title":"OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-Overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1","volume":"19","author":"Planchard","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2025.43.16_suppl.8501","article-title":"TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) plus Pembrolizumab (Pembro) with or without Platinum Chemotherapy (Pt-CT) as First-Line (1L) Therapy for Advanced Non-Small Cell Lung Cancer (ANSCLC)","volume":"43","author":"Levy","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","article-title":"TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) plus Pembrolizumab (Pembro) with or without Platinum Chemotherapy (Pt-CT) in Advanced Non-Small Cell Lung Cancer (ANSCLC)","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1080\/14796694.2024.2409621","article-title":"TROPION-Lung07: Phase III Study of Dato-DXd + Pembrolizumab \u00b1 Platinum-Based Chemotherapy as 1L Therapy for Advanced Non-Small-Cell Lung Cancer","volume":"20","author":"Okamoto","year":"2024","journal-title":"Future Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/j.jtho.2023.09.525","article-title":"P2.04-02 AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced\/MNSCLC","volume":"18","author":"Aggarwal","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.esmoop.2025.104164","article-title":"8O First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) + Durvalumab \u00b1 Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (a\/MNSCLC): Results from TROPION-Lung04 (Cohorts 2 and 4)","volume":"10","author":"Cuppens","year":"2025","journal-title":"ESMO Open"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Collados-Ros, A., Muro, M., and Legaz, I. (2024). Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms\u2014A Systematic Review. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010208"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/blood-2024-210605","article-title":"A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia","volume":"144","author":"Borate","year":"2024","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/bjh.19436","article-title":"Gemtuzumab Ozogamicin plus Midostaurin in Combination with Standard \u20187 + 3\u2019 Induction Therapy in Newly Diagnosed AML: Results from the SAL-MODULE Phase I Study","volume":"204","author":"Schliemann","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/blood-2024-193442","article-title":"Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","volume":"144","author":"Patel","year":"2024","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-023-01444-2","article-title":"Results of Salvage Therapy with Mini-Hyper-CVD and Inotuzumab Ozogamicin with or without Blinatumomab in Pre-B Acute Lymphoblastic Leukemia","volume":"16","author":"Kantarjian","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2024-210501","article-title":"Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed\/Refractory B-Cell ALL","volume":"144","author":"Habib","year":"2024","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S2152-2650(24)01140-6","article-title":"ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic Leukemia","volume":"24","author":"Jabbour","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e67564ca","DOI":"10.1097\/01.HS9.0000968344.67564.ca","article-title":"P358: Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: A phase II study","volume":"7","author":"Short","year":"2023","journal-title":"HemaSphere"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e19017","DOI":"10.1200\/JCO.2023.41.16_suppl.e19017","article-title":"A Phase II Study of Hyper-CVAD with Blinatumomab (Blina) and Inotuzumab Ozogamicin (INO) for Newly Diagnosed Philadelphia Chromosome (Ph)\u2013Negative B-Cell Acute Lymphoblastic Leukemia (ALL)","volume":"41","author":"Short","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2024-197938","article-title":"Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes","volume":"144","author":"Salles","year":"2024","journal-title":"Blood"},{"key":"ref_156","unstructured":"(2025, September 01). Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-previously-untreated-diffuse-large-b-cell-lymphoma-not."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/bloodadvances.2022009145","article-title":"Polatuzumab Vedotin with Infusional Chemotherapy for Untreated Aggressive B-Cell Non-Hodgkin Lymphomas","volume":"7","author":"Lynch","year":"2023","journal-title":"Blood Adv."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2024-198624","article-title":"Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double\/Triple Hit Lymphoma","volume":"144","author":"Diefenbach","year":"2024","journal-title":"Blood"},{"key":"ref_159","first-page":"2802","article-title":"Spotlight on Polatuzumab Vedotin: New Standards for Diffuse Large B-Cell Lymphoma?","volume":"109","author":"Ghione","year":"2024","journal-title":"Haematologica"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hon.70094_280","article-title":"Glofitamab combined with R-Chop or POLA-R-CHP in patients with previously untreated diffuse large B-cell lymphoma: Final results from the NP40126 study","volume":"43","author":"Topp","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO-25-00481","article-title":"Glofitamab Combined with Pola-R-CHP or R-CHOP as First Therapy in Younger Patients with High-Risk Large B-Cell Lymphoma: Results from the COALITION Study","volume":"43","author":"Minson","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1182\/blood-2024-194000","article-title":"SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)","volume":"144","author":"Advani","year":"2024","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.4103\/jcrt.jcrt_269_24","article-title":"Polatuzumab Vedotin plus Bendamustine and Rituximab in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: A Phase III Bridging Study in Chinese Patients","volume":"20","author":"Song","year":"2024","journal-title":"J. Cancer Res. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e829_70096","DOI":"10.1002\/hon.70096_829","article-title":"829|Phase Ib clinical trial of loncastuximab tesirine and roflumilast in added to R-CHOP (Lo-RR-CHOP) for treatment naive high risk diffuse large B cell lymphoma","volume":"43","author":"Aguiar","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FR\u03b1)\u2013Targeting Antibody-Drug Conjugate, in Combination with Carboplatin and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hon.3163_T03","article-title":"Brentuximab Vedotin-Nivolumab Alone and Then with Rituximab-Cyclophosphamide-Doxorubicin-Prednisone as Frontline Therapy of Primary Mediastinal Large B-cell Lymphoma","volume":"41","author":"Steiner","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_167","first-page":"1194","article-title":"Polatuzumab Vedotin plus Bendamustine and Rituximab or Obinutuzumab in Relapsed\/Refractory Follicular Lymphoma: A Phase Ib\/II Study","volume":"109","author":"Flowers","year":"2023","journal-title":"Haematologica"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.annonc.2024.05.412","article-title":"500TiP An Open Label Phase Ib\/II Study of Trastuzumab Deruxtecan (T-DXd) in Combination with Nivolumab and CAPOX for Patients with HER2-Low Expressing Gastroesophageal Adenocarcinoma (EPOC2203)","volume":"35","author":"Aoki","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/S1556-0864(25)00327-2","article-title":"132TiP: Phase Ib Open-Label Study of Trastuzumab Deruxtecan (T-DXd) + Rilvegostomig \u00b1 Carboplatin as First-Line (1L) Treatment (Tx) for Metastatic HER2-Overexpressing (HER2-OE) Non-Small Cell Lung Cancer (NSCLC): DESTINY-Lung03 (DL-03) Part 4","volume":"20","author":"Planchard","year":"2025","journal-title":"J. Thorac. Oncol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/12\/1581\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:14:42Z","timestamp":1765430082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/12\/1581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":169,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pharmaceutics17121581"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17121581","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}